A Time to Cardiovascular Event Analysis Comparing Tocilizumab to Other Biologics in Patients With Rheumatoid Arthritis (RA)
- Sponsor
- Hoffmann-La Roche
- Study ID
- NCT02797769
- Status
- Completed
Conditions
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Other Biologics — DRUGExposure data will be gathered from claims databases, and no medicine will be administered in this non-interventional study. There are no protocol-specified biologic agents, although the analyses will be stratified by TNFi and non-TNFi targeted therapies. The drug selection and regimen are at the discretion of the prescribing physician.
- Tocilizumab — DRUGTocilizumab exposure data will be gathered from claims databases, and no medicine will be administered in this non-interventional study. The regimen is at the discretion of the prescribing physician.
Study Details
This retrospective cohort study will analyze data from multiple large U.S. health insurance claims databases to compare use of tocilizumab to other biologic disease-modifying anti-rheumatic drugs (DMARDs) in real world patients with RA. Using the date of dispensing as the index date, the analysis will compute the time to first event for several cardiovascular outcomes.
Key Dates
- Start date
- Jun 2, 2016
- Status verified
- Jan 2023
- Primary completion
- Jun 2, 2016
- Completion
- Jun 2, 2016
Study Design
- Enrollment
- 48,950 participants (actual)
Arms
- Arm: Non-TNFi BiologicsReal world patients with RA with a dispensing history for non-TNFi biologics (such as abatacept or tofacitinib) will be included.
- Arm: TNFi BiologicsReal world patients with RA with a dispensing history for TNFi biologics will be included.
- Arm: TocilizumabReal world patients with RA with a dispensing history for tocilizumab will be included.
Primary Outcome Measure
Time to First Event of Myocardial Infarction (MI) or Stroke with Tocilizumab Versus Tumor Necrosis Factor Inhibitor (TNFi) Therapies [ Time Frame: Up to approximately 1 year from index date ]
Related Studies
- CorEvitas Rheumatoid Arthritis (RA) Drug Safety & Effectiveness RegistryEnrolling By Invitation · CorEvitas · Waltham, Massachusetts
- Physica System Total Knee Replacement Registry StudyRecruiting · Limacorporate S.p.a · Rancho Mirage, California
- Early Rheumatoid Arthritis Lung Disease StudyRecruiting · University of Nebraska · Omaha, Nebraska
- Maternal Autoimmune Disease Research Alliance (MADRA) RegistryRecruiting · Duke University · Durham, North Carolina